Communiqués Mesoblast Limited

Actions

MSB

AU000000MSB8

Marché Fermé - Australian S.E. Autres places de cotation 08:11:03 07/06/2024			Varia. 5j.	Varia. 1 janv.
1,045 ^AUD	+1,95 %		-5,86 %	+237,10 %

01/05	Mesoblast Limited annonce des changements au sein de son conseil d'administration et de ses comités	CI
26/03	La FDA déclare que les données de l'étude de Mesoblast sont suffisantes pour soutenir la soumission d'une BLA	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Mesoblast Corporate Presentation at Investor Conference	03/06	AQ
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024	30/04	AQ
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK	28/03	AQ
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)	26/03	AQ
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer	14/03	AQ
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)	11/03	AQ
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023	28/02	AQ
Mesoblast Financial Results and Corporate Update Webcast	26/02	AQ
MESOBLAST - UNITED STATES FOOD & DRUG ADMINISTRATION GRANTS MESOBLAST ORPHAN-DRUG DESIGNATION FOR REVASCOR IN CHILDREN WITH CONGENITAL HEART DISEASE	15/02	AQ
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	15/02	AQ
MESOBLAST LIMITED - APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED DECEMBER 31, 2023	31/01	AQ
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023	31/01	AQ
MESOBLAST - UNITED STATES FOOD AND DRUG ADMINISTRATION GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR IN CHILDREN WITH CONGENITAL HEART DISEASE	19/01	AQ
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	19/01	AQ
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease	27/11	AQ
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD	22/11	AQ
MESOBLAST - APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED SEPTEMBER 30, 2023	31/10/23	AQ
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023	31/10/23	AQ
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee	26/09/23	AQ
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval	21/09/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Mesoblast Limited

Actions

MSB

AU000000MSB8

Communiqués

Filtres